HKSE - Delayed Quote HKD

Brii Biosciences Limited (2137.HK)

1.000

-0.030

(-2.91%)

At close: 4:08 PM GMT+8

Brii Bio Delivers First Head-to-Head Comparison of siRNA (Elebsiran) and PEG-IFNα Combination versus PEG-IFNα Alone at AASLD's The Liver Meeting® 2024, Demonstrating Higher Loss of HBV Surface Antigen by Combining with siRNA

Brii Biosciences Limited ("Brii Bio," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs, announced new data from its ongoing Phase 2 ENSURE study as a late-breaking oral presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place from November 15 - 19 in San Diego, CA.

PR Newswire 2 days ago

BRIBF
Top Penny Stocks To Watch In November 2024

Global markets have experienced significant shifts, with U.S. stocks rallying to record highs following a Republican "red sweep" in the recent elections, sparking hopes for growth and tax reforms. Amid these changes, investors are increasingly seeking opportunities in smaller or newer companies often referred to as penny stocks—a term that may sound outdated but remains relevant today. These stocks can offer growth potential at lower price points, especially when they possess strong...

Simply Wall St. 8 days ago

F03.SI

0673.HK

BRIBF
Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024

Brii Biosciences Limited ("Brii Bio," "we," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs, presented new data from two Phase 2 studies evaluating BRII-179 either as a combination therapy with BRII-835 (elebsiran) or as an add-on therapy to pegylated interferon-alpha (PEG-IFNα) treatment for chronic hepatitis B virus (HBV) infection at the EASL™ (European Association for the Study of

PR Newswire 5 months ago

BRIBF
Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies

Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) granted Breakthrough Therapy Designations for BRII-877 (tobevibart), an investigational broadly neutralizing monoclonal antibody targeting hepatitis B virus (HBV) and BRII-835 (elebsiran), a

PR Newswire 6 months ago

BRIBF
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results

Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, today provided a corporate update and reported its financial results for the year ended December 31, 2023.

PR Newswire 7 months ago

BRIBF
Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies

Brii Biosciences Limited ("Brii Bio," "we," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs, today announced that it has entered into agreements with VBI Vaccines, Inc. ("VBI", NASDAQ: VBIV), ensuring expansion and control of future clinical and commercial supplies of BRII-179, a late-stage clinical asset in Brii Bio's HBV functional cure portfolio.

PR Newswire 9 months ago

BRIBF
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer

Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, is pleased to announce the appointment of Dr. Brian Alvin Johns, Ph.D., as Chief Scientific Officer, effective January 3, 2024. Dr. Johns will oversee the discovery programs at Brii Bio and set the company's future pipeline strategy and priority.

PR Newswire 10 months ago

BRIBF

Performance Overview

Return	2137.HK	HANG SENG INDEX
YTD	-56.14%	+12.80%
1-Year	-65.28%	+8.44%
3-Year	-97.25%	-23.23%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Brii Biosciences Limited (2137.HK)

Brii Bio Delivers First Head-to-Head Comparison of siRNA (Elebsiran) and PEG-IFNα Combination versus PEG-IFNα Alone at AASLD's The Liver Meeting® 2024, Demonstrating Higher Loss of HBV Surface Antigen by Combining with siRNA

Top Penny Stocks To Watch In November 2024

Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024

Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies

Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results

Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies

Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer

Performance Overview